Messina M, et al. - The purpose of conducting this study was to assess the impact of once-daily administration of chitosan-N-acetylcysteine (Lacrimera) in the management of dry eye disease (DED). Patients suffering from DED from a variety of causes, who were refractory to standard treatment with lubricants demonstrated improved signs and symptoms by a single-dose instillation of chitosan-N-acetylcysteine for 5 consecutive days. In patients with moderate to severe DED experts emphasized on considering Lacrimera as a viable option, on account of its posology, the absence of side effects and the results obtained.